There are 2934 resources available
3665 - Prescription and Treatment Patterns of Lenvatinib (L) in Patients with Radioactive Iodine-Refractory Differentiated Thyroid Cancer (rDTC): A Retrospective Analysis of the Canadian Patient Support Program (PSP)
Presenter: Sebastien Hotte
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
4991 - Relation between objective tumor shrinkage and progression-free survival (PFS) in the NETTER-1 population
Presenter: Marianne Pavel
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5796 - Phase I Study of CC-90011 in Patients With Advanced Solid Tumors (STs) and Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL)
Presenter: Antoine Hollebecque
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5891 - New circulating biomarkers in Gastro-Entero-Pancreatic-Neuroendocrine-Tumors
Presenter: Martine Bocchini
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
3362 - Impact of lung metastasis on overall survival (OS) in the phase 3 SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC)
Presenter: Makoto Tahara
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
Presentation by expert
Presenter: Vincent Launay-Vacher
Session: Drug interaction and the key role of kidney function in onco-haematology
Resources:
Slides
Webcast
Discussion led by Chair
Presenter: Miklos Pless
Session: How do we personalise treatment in stage III NSCLC?
Resources:
Slides
Webcast
2034 - Specific patterns of long non-coding RNA expression in benign and malignant thyroid nodules
Presenter: Valentina Yakushina
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
5072 - Spatiotemporal intratumor genetic heterogeneity and clonal evolution in PTCs and paired DM
Presenter: Sara Gil Bernabé
Session: Poster Discussion – NETs and endocrine tumours
Resources:
Abstract
1433 - Comprehensive pan-cancer analysis of KRAS genomic alterations (GA) including potentially targetable subsets
Presenter: Sai-Hong Ou
Session: Poster Discussion 2 – Translational research
Resources:
Abstract